Oncolytics Biotech Inc T.ONC

mBC Phase III

[Quentin30]

Who wants to bet that in early 2024, ONCY will announce that from that point onwards, they will be focusing solely on Pancreatic Cancer ?

Since they will no longer be running a breast cancer trial with a CPI, the data is in. The data is already in from IND-213... which is now 5+ years old...  5 years, and the partner willing to pony up for the Phase III is (round of applause...), and the partner willing to pony up for the Phase III trial is... (another round of applause - think Von Trapp family singers moment at the Vienna music festival).

Perhaps the announcement of canning that project will come as early as the next quarterly update... 

roll on 2024.

[ONCInvestor]

It will depend partly on the OS data for Bracelet. That said, if the company has to choose an indication to focus on, it will be pancreatic for cost reasons alone. That would be my choice, at least. That said, if they are running any P3s themselves in 2024, then we all have a bigger problem.

[jimsenior]

cathy on yahoo nailed it. No matter how you slice it, this move smacks of weakness, and has left a broken stock even weaker, and vulnerable. They did not extend the warrants for those of us who have been supporting the company for years. Perhaps there is something that does not meet the eye, but I doubt it. Unlike cathy, I will not be adding shares. They have fumbled this for decades. MC better

[westcoast1000]

cathy said it was self enrichment. I do not see any evidence of that. Keeping the company going 4-6 months longer is not self enrichment, given where we are with the results. But it does seem like weakness. 

[JohnnyYeg]

This move is NOT weakness.... expect news to follow very shortly. It will be surprising